NCT07845604From ClinicalTrials.govRecruiting

Precision Depression Adalimumab Trial

An Precision Immunopsychiatric Pharmacological Probe of Adalimumab as an Anti-depressant

Major Depressive Disorder (MDD)

At a glance

Phase: Phase 2
Study type: Interventional
Sponsor: Daniel Moriarity
Enrolment target: 60
Started: September 2026
Main results due: July 2031
Study sites: 1
Registry updated: 29 September 2026

Can you take part?

Aged 18 years and over.
Open to any sex.
You need the condition being studied — healthy volunteers are not accepted.

These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.

Read the full eligibility criteria

Inclusion Criteria:

* Provision of signed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Male or female, aged 18+ years
* Meet DSM-5 criteria for Major Depressive Disorder
* baseline serum TNF-alpha (average of two samples in the same week) greater than 1.5 pg/mL
* Taking a steady dose of Lexapro (escitalopram) for at least 4 weeks
* Ability to take oral medication and physician-administered subcutaneous injection and be willing to adhere to the study protocol
* For females of reproductive potential: use of highly effective contraception for at least 1 month
* Access to a phone or computer with a camera

Exclusion Criteria:

1. Pregnant or breastfeeding
2. Active, chronic or recurrent infection
3. Known malignancy
4. Current use of immune modulating medications
5. Immunocompromised, current autoimmune condition or history of severe immune condition (e.g., history of cancer, HIV/AIDS)
6. History of, or positive test for, Hepatitis B surface antigen or core antibody positivity or tuberculosis (TB)
7. Congestive heart failure
8. History of demyelinating disease (multiple sclerosis (MS), optic neuritis, Guillain-Barre syndrome)
9. History of seizure disorder
10. Symptomatic hyponatremia
11. Monoamine oxidase inhibitors (MAOI) use within 14 days
12. Recent use of Rituxan (rituximab)
13. Concomitant use of:

    1. Immunosuppressants
    2. Kineret (anakinra)
    3. Orencia (abatacept)
    4. Remicade (infliximab)
    5. Enbrel (etanercept)
    6. Cimzia (certolizumab pegol)
    7. Simponi (golimumab)
    8. Imuran (azathioprine)
    9. Purinethol (6-mercaptopurine)
    10. Linezolid
    11. IV methylene blue
    12. Pimozide
    13. Antiplatelet agents
    14. Strong anticoagulants (e.g. warfarin, large doses of NSAIDs)
    15. Other SSRIs, SNRIs, tryptophan
14. Clinically relevant substance use disorder
15. Known allergic reactions to components of adalimumab and/or escitalopram
16. Treatment with another investigational drug or other intervention while participating in the study

What this study is about

In the sponsor’s own words, from the registry.

The goal of this clinical trial is to learn if the anti-inflammatory medication adalimumab improves depressive symptoms in adults with Major Depressive Disorder (MDD) who are already taking the anti-depressant medication Lexapro (escitalopram).

The main questions it aims to answer are:

1. Does adalimumab improve the symptoms of some patients with MDD who are already taking an anti-depressant? 2. What characteristics predict for whom adalimumab has anti-depressant properties.

Researchers will compare adalimumab to a placebo (a look-alike substance that contains no drug) to see if adalimumab works to improve depressive symptoms as an add-on drug to the anti-depressant Lexapro (escitalopram).

For these primary aims the participants will:

1. Visit the clinic once every 2 weeks for a checkups and injection of adalimumab or placebo from the study psychiatrist (Day 1, 15, 29, and 43 for injections) 2. Complete short (\<5 min) daily surveys for the 57 day duration of the study.

Study sites(1)

University of Pennsylvania
Philadelphia, Pennsylvania, United States
Recruiting

Showing 1 of 1 sites. 1 of the 1 site on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.

Source: ClinicalTrials.gov record NCT07845604. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Not the right study?

Answer three questions and see the studies recruiting near you, in plain language.

Find a study for me